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Summary
Background: Pneumocystis pneumonia (PCP) caused by Pneumocystis jiroveci is common in HIV-
infected children, producing substantial morbidity and mortality. Initiation of timely, effective
therapy depends on clinical identification of children with PCP.
Objective: To develop a clinical decision rule to diagnose PCP in HIV-infected children for use
where diagnostic resources are limited.
Methods: Analysis of data collected during a prospective incidence study of the etiology,
features, and outcome of HIV-infected children hospitalized with pneumonia.
Results: Four clinical variables were independently associated with a diagnosis of PCP in
multivariate analysis: age <6 months (OR 15.6; 95% CI 2.4—99.8; p = 0.004), respiratory rate
>59 breaths/min (OR 8.1; 95% CI 1.5—53.2; p = 0.018), arterial percentage hemoglobin oxygen
saturation (SaO2) 92% (OR 5.1; 95% CI 1.0—26.1; p = 0.052) and absence of history of vomiting
(OR 11.2; 95% CI 1.9—68.0; p = 0.008). The sensitivity and specificity of diagnosing PCP with any
two or more of these variables were 1.00 (95% CI 0.74—1.00) and 0.49 (95% CI 0.39—0.59),
respectively. Diagnosing PCP with three or more of the indicators had a decreased sensitivity of
0.75 (95% CI 0.43—0.95) and increased specificity of 0.90 (95% CI 0.83—0.95).
Conclusion: Empirical anti-pneumocystis therapy should be considered in HIV-infected infants
presenting with tachypnea, hypoxia and absence of vomiting.
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Pneumocystis pneumonia (PCP) caused by Pneumocystis jir-
oveci infection, is an important cause of morbidity and
mortality amongst HIV-infected children in Africa. Post-mor-
tem studies have found PCP to be the cause of 29—67% of
respiratory related deaths amongst HIV-infected children,1—3
and in-hospital case-fatality rates for PCP have ranged from
20—63%.4—8 The prevalence of PCP amongst HIV-infected
children hospitalized with pneumonia in Africa has varied
from 10—49%.4—8
The case-fatality rate of children with untreated PCP
approximates to 100%, therefore diagnosing and treating
children at risk is essential.9 Effective, specific first-line
therapy for PCP consists of trimethoprim—sulfamethoxazole
with or without corticosteroids. Definitive diagnosis of PCP in
resource-limited areas is difficult, due to a lack of diagnostic
resources and expertise,1,4,7,8 and management decisions for
children with pneumonia must bemade primarily on a clinical
basis. It is therefore important to define a valid clinical
diagnostic technique for PCP that could be used by clinicians
in resource-limited areas, enabling timely use of empirical
anti-pneumocystis therapy.
Certain presenting clinical characteristics have previously
been found in HIV-infected children with PCP compared with
pneumonia of other etiologies. Graham and colleagues found
Malawian children with PCP had a significantly lower median
age, oxygen saturation and body temperature; higher pro-
portions had no abnormality or diffuse abnormality on aus-
cultation, compared with children with pneumonia of other
etiologies.8 South African children with PCP have been
reported to have a lower median age, and infants with
PCP to have increased respiratory rates.6 Amongst Botswanan
children who died from respiratory disease, age 1 year and
pulmonary infiltrates on chest radiograph were predictive of
PCP.2
The aim of this study was to develop a clinical decision
rule,10 using a combination of clinical criteria, which could be
used in resource-limited areas, to differentiate PCP from
pneumonia of other etiologies in HIV-infected children.
Methods
Data collected during a prospective incidence study that
aimed to compare the etiology, associated clinical, labora-
tory, radiological features and outcome of children hospita-
lized with pneumonia,4,5 were re-analyzed. Data collection
occurred at four hospitals forming part of the University of
Cape Town teaching hospitals complex in Cape Town, South
Africa. Consecutive children below ten years of age, with a
primary diagnosis of pneumonia or severe pneumonia, and
who were known to be HIV-infected, were suspected of
having HIV infection, or were admitted to the intensive care
unit, were included prospectively between January and
December 1998.
Socio-demographic and clinical data were obtained on
admission and captured on standardized data capture forms.
Hematological and serum chemistry parameters, measure-
ment of arterial oxygen saturation in room air, blood bacter-
ial cultures, HIV testing, and chest radiography were
performed on inclusion in the study. Induced sputum andnasopharyngeal aspirate specimens were obtained, and non-
directed bronchoalveolar lavage was performed in intubated
children. Specimens were submitted for detection of P.
jiroveci using a silver methenamine stain and immunofluor-
escence, and PCP was diagnosed with positive microscopy
using either technique, from either bronchoalveolar lavage
fluid or induced sputum. These specimens were also sub-
mitted for bacterial, viral, fungal and mycobacterial culture,
and the nasopharyngeal aspirate submitted for bacterial
culture.
For this analysis, the multivariate associations of clinical,
laboratory and radiological variables with respect to PCP
were analyzed using logistic regression, to identify the com-
bination of variables that best predicted PCP. The variables
thus selected were used to calculate the sensitivity, speci-
ficity, predictive values, and interval likelihood ratios for
combinations of differing numbers of these variables with
respect to a diagnosis of PCP, each variable being assigned an
equal weighting. Continuous variables in the final model were
categorized, with cut-off values chosen that are clinically
easily applicable and that maximized differences in the
outcome. Post-test (or post-rule) probabilities of PCP were
estimated for varying prevalences of PCP by applying Bayes’
theorem. The University of Cape Town research and ethics
committee granted ethical approval for this analysis, and for
the original data collection study.
Results
One hundred and fifty-one HIV-infected children with a
median age of 9 months (Interquartile range 3—23 months)
were enrolled. There were 80 (53%) males and 71 females.
Fifteen childrenwere found to have PCP, accounting for 9.9%
(95% CI 5.9—15.5%) of pneumonia cases in the sample. Other
organisms cultured from respiratory secretions included
Staphylococcus aureus (15.0%), Klebsiella pneumoniae
(10.9%), Haemophilus influenzae (8.8%), Mycobacterium
tuberculosis (7.4%) and cytomegalovirus (14.3%). Fifty-nine
(39.1%) children were taking trimethoprim—sulfamethoxa-
zole prophylaxis.
Four variables were found to be independent risk factors
for a diagnosis of PCP: age <6 months (OR 15.6; 95% CI 2.4—
99.8; p = 0.004), respiratory rate >59 breaths/min (OR 8.1;
95% CI 1.5—53.2; p = 0.018), arterial hemoglobin oxygen
saturation 92% (OR 5.1; 95% CI 1.0—26.1; p = 0.052) and
absence of history of vomiting at presentation (OR 11.2; 95%
CI 1.9—68.0; p = 0.008). The final model included 116 chil-
dren (12 with PCP and 104 without); the remaining partici-
pants were not included due to missing observations not
recorded during data collection (complete-subjects method
of logistic regression). This model had an area under the
receiver-operating characteristic curve of 0.92. No labora-
tory results or radiological features were independently
associated with PCP.
Using a dichotomous diagnostic test outcome, the sensi-
tivity and specificity of diagnosing PCP with any two or more
of these indicator variables were 1.00 (95% CI 0.74—1.00) and
0.49 (95% CI 0.39—0.59), respectively. Diagnosing PCP with
three or more of the indicators had a decreased sensitivity of
0.75 (95% CI 0.43—0.95) but increased specificity of 0.90 (95%
CI 0.83—0.95).
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Table 1 Interval likelihood ratios and post-test probabilities of PCP with varying pre-test probabilities of PCP, according to the
number of clinical indicators present in a child
Number of
indicators
Interval likelihood
ratio (95% CI)
Post-test probabilities, % (95% CI) of PCP with differing pre-test
probabilities of PCP
If pre-test
probability = 10%
If pre-test
probability = 20%
If pre-test probability =
49% (severe pneumonia)
0 0 0 0 0
Any 1 0 0 0 0
Any 2 0.6 (0.2—1.7) 7 (2—16) 13 (5—30) 38 (18—62)
Any 3 5.0 (2.0— 12.5) 36 (18—58) 56 (33—76) 83 (66—92)
All 4 36.0 (4.4—96.5) 80 (33—97) 90 (52—96) 97 (81—99)
Three pre-test probabilities of PCPhave been used: the samples’ proportion of PCP (10%), themaximum reported proportion of PCPamongst
HIV-infected children hospitalized with pneumonia (49%), and an intermediate value of 20%.The interval likelihood ratios of hierarchical categories
according to the number of indicators present in a child, and
the associated post-test probabilities of PCP (Table 1), were a
more informative measure of diagnostic accuracy. Interval
likelihood ratios are a measure of the degree to which the
probability of the condition of interest changes, given a test
result or number of clinical indicators present. Post-test
probability describes the prevalence of PCP among the sub-
groups of childrenwith any one, two, three or four indicators,
respectively. Post-test probabilities of PCP vary according to
the interval likelihood ratio of each subgroup, and the pre-
test probability of PCP. The pre-test probability of PCP is the
burden of disease in the population at risk, being 10% in this
sample. The proportion of PCP in HIV-infected children in
Africa has been reported to be as high as 49% amongst
children with severe pneumonia.7 Post-test probabilities of
PCP were calculated using these two values as pre-test
probabilities of PCP. For illustrative purposes, an intermedi-
ate pre-test probability of 20% has been included. The inter-
val likelihood ratio associated with none, or any one of the
indicators being present was zero, with resulting post-test
probabilities of PCP of 0%, irrespective of the pre-test prob-
ability (confidence intervals cannot be calculated). The pre-
sence of any three of the indicators had an interval likelihood
ratio of 5.0 (95% CI 2.0—12.5), with a post-test probability of
PCP of 36% (95% CI 18—58%) in the sample. All four variables
being present had an interval likelihood ratio of 36.0 (95% CI
4.4—96.5), with a post-test probability of PCP of 80% (95% CI
33—97%) in this sample. Post-test probabilities increase pro-
gressively with increasing pre-test probabilities of PCP.
Discussion
Foureasilymeasured clinical variableswere identified that are
independent risk factors for PCP in HIV-infected children
hospitalized with pneumonia. The presence of none, or any
oneof the indicators ina child is associatedwitha lowpost-test
probability of PCP, and any three or all four indicators with
increased probabilities of PCP. This analysis provides prelimin-
ary evidence in the clinical prediction of PCP in HIV-infected
children with pneumonia, and has importance for the devel-
opment of a clinical decision rule for use in areas that do not
have access to definitive diagnostic resources for PCP.
Young age as a risk factor for PCP is consistent with previous
reports.2,6,8 Hypoxia is a well documented clinical sign due toextensive interstitial pneumonia, and has been reported as
being more severe in children with PCP than with bacterial
pneumonia.8 Tachypnea is a reflection of the degree of
hypoxia. The association of the absence of history of vomiting
with PCP was however an unexpected finding, which has not
been measured by other researchers. Vomiting may be a
feature of lower respiratory tract infections where hyperin-
flation predominates, resulting in a flattened diaphragm and a
compressed stomach, whereas hyperinflation is not usually
associated with PCP. Children who have vomited may also be
more likely to have aspiration pneumonia rather than PCP.
The measures of diagnostic accuracy of this analysis are
imprecise, indicating a lack of statistical power, and the
results have not yet been validated, therefore definitive
clinical management recommendations cannot be based on
the results at this stage. These findings however suggest that
empirical anti-pneumocystis therapy should be considered in
an HIV-infected child presenting with tachypnea, hypoxia and
absence of vomiting. Further studies should be undertaken to
validate these findings, and to quantify diagnostic accuracy
with improved precision.
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